Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial

Crohn's disease (CD) patients included in the TAILORIX trial started infliximab in combination with an immunosuppressant for one year. The aim of the present study was to determine the long-term disease course beyond the study period.

Source: Clinical Gastroenterology and Hepatology - November 26, 2021 Category: Gastroenterology Authors: David Laharie, Geert D ’Haens, Maria Nachury, Guy Lambrecht, Peter Bossuyt, Yoram Bouhnik, Edouard Louis, Christien Janneke van der Woude, Anthony Buisson, Philippe Van Hootegem, Matthieu Allez, Jérôme Filippi, Hedia Brixi, Cyrielle Gilletta, Laurence Source Type: research